 MONT-SAINT-GUIBERT, Belgium, May 17, 2022 GLOBE NEWSWIRE -- Celyad Oncology SA Euronext Nasdaq: CYAD the Company, a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell CAR T therapies for cancer, today announced that the Company plans to participate virtually at the upcoming H.C. Wainwright Global Investment Conference, May 23 26, 2022. 